Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway

References

• Boyle GM Therapy for metastatic melanoma: an overview and update Expert Rev Anticancer Ther 2011 11 5 725 737 21554048
   PubMed Web of Science ®Google Scholar
• Falkson CI Ibrahim J Kirkwood JM Coates AS Atkins MB Blum RH Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study J Clin Oncol 1998 16 5 1743 1751 9586887
   PubMed Web of Science ®Google Scholar
• Atkins MB Hsu J Lee S Eastern Cooperative Oncology Group Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 2008 26 35 5748 5754 19001327
   PubMed Web of Science ®Google Scholar
• Eigentler TK Caroli UM Radny P Garbe C Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol 2003 4 12 748 759 14662431
   PubMed Web of Science ®Google Scholar
• Serrone L Zeuli M Sega FM Cognetti F Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview J Exp Clin Cancer Res 2000 19 1 21 34 10840932
   PubMed Web of Science ®Google Scholar
• Hauschild A Agarwala SS Trefzer U Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 2009 27 17 2823 2830 19349552
   PubMed Web of Science ®Google Scholar
• Pectasides D Yianniotis H Alevizakos N Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin Br J Cancer 1989 60 4 627 629 2803936
   PubMed Web of Science ®Google Scholar
• Hamm C Verma S Petrella T Bak K Charette M Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review Cancer Treat Rev 2008 34 2 145 156 18077098
   PubMed Web of Science ®Google Scholar
• Davies H Bignell GR Cox C Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954 12068308
   PubMed Web of Science ®Google Scholar
• Smalley KS Understanding melanoma signaling networks as the basis for molecular targeted therapy J Invest Dermatol 2010 130 1 28 37 19571822
   PubMed Web of Science ®Google Scholar
• Chapman PB Hauschild A Robert C BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAFV600E mutation N Engl J Med 2011 364 26 2507 2516 21639808
   PubMed Web of Science ®Google Scholar
• Houslay MD Hard times for oncogenic BRAF-expressing melanoma cells Cancer Cell 2011 19 1 3 4 21251608
   PubMed Web of Science ®Google Scholar
• Ribas A Flaherty KT BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 2011 8 7 426 433 21606968
   PubMed Web of Science ®Google Scholar
• Bollag G Tsai J Zhang J Vemurafenib: the first drug approved for BRAF-mutant cancer Nat Rev Drug Discov 2012 11 11 873 886 23060265
   PubMed Web of Science ®Google Scholar
• Nikolaou VA Stratigos AJ Flaherty KT Tsao H Melanoma: new insights and new therapies J Invest Dermatol 2012 132 3 Pt 2 854 863 22217739
   PubMed Web of Science ®Google Scholar
• Smalley KS Sondak VK Melanoma – an unlikely poster child for personalized cancer therapy N Engl J Med 2010 363 9 876 878 20818849
   PubMed Web of Science ®Google Scholar
• Nazarian R Shi H Wang Q Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 2010 468 7326 973 977 21107323
   PubMed Web of Science ®Google Scholar
• Johannessen CM Boehm JS Kim SY COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 2010 468 7326 968 972 21107320
   PubMed Web of Science ®Google Scholar
• Poulikakos PI Persaud Y Janakiraman M RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 2011 480 7377 387 390 22113612
   PubMed Web of Science ®Google Scholar
• Shi H Moriceau G Kong X Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 2012 3 724 22395615
   PubMed Web of Science ®Google Scholar
• Emery CM Vijayendran KG Zipser MC MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 2009 106 48 20411 20416 19915144
   PubMed Web of Science ®Google Scholar
• Paraiso KH Xiang Y Rebecca VW PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 2011 71 7 2750 2760 21317224
   PubMed Web of Science ®Google Scholar
• Villanueva J Vultur A Lee JT Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 2010 18 6 683 695 21156289
   PubMed Web of Science ®Google Scholar
• Jiang CC Lai F Thorne RF MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720 Clin Cancer Res 2011 17 4 721 730 21088259
   PubMed Web of Science ®Google Scholar
• Madonna G Ullman CD Gentilcore G Palmieri G Ascierto PA NF-κB as potential target in the treatment of melanoma J Transl Med 2012 10 53 22433222
   PubMed Web of Science ®Google Scholar
• Flaherty KT Infante JR Daud A Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 2012 367 18 1694 1703 23020132
   PubMed Web of Science ®Google Scholar
• Falchook GS Lewis KD Infante JR Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 2012 13 8 782 789 22805292
   PubMed Web of Science ®Google Scholar
• Infante JR Fecher LA Falchook GS Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 2012 13 8 773 781 22805291
   PubMed Web of Science ®Google Scholar
• Shimizu T Tolcher AW Papadopoulos KP The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer Clin Cancer Res 2012 18 8 2316 2325 22261800
   PubMed Web of Science ®Google Scholar
• Pollak M The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat Rev Cancer 2012 12 3 159 169 22337149
   PubMed Web of Science ®Google Scholar
• Pollak M The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology Clin Cancer Res 2012 18 1 40 50 22215905
   PubMed Web of Science ®Google Scholar
• Chen J Katsifis A Hu C Huang XF Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway Curr Drug Discov Technol 2011 8 2 119 125 21513489
   PubMedGoogle Scholar
• Chen J Huang XF Qiao L Katsifis A Insulin caused drug resistance to oxaliplatin in colon cancer cell HT29 J Gastrointest Oncol 2011 2 1 27 33 22811824
   PubMedGoogle Scholar
• Gillespie S Zhang XD Hersey P Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis Mol Cancer Ther 2005 4 4 668 676 15827341
   PubMed Web of Science ®Google Scholar
• Tay KH Jin L Tseng HY Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress Cell Death Dis 2012 3 e337 22739989
   PubMed Web of Science ®Google Scholar
• Serrone L Zeuli M Sega FM Cognetti F Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview J Exp Clin Cancer Res 2000 19 1 21 34 10840932
   PubMed Web of Science ®Google Scholar
• York RM Foltz AT Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma Cancer 1988 61 11 2183 2186 2452681
   PubMed Web of Science ®Google Scholar
• Taylor SI Leventhal S Defect in cooperativity in insulin receptors from a patient with a congenital form of extreme insulin resistance J Clin Invest 1983 71 6 1676 1685 6345588
   PubMed Web of Science ®Google Scholar
• Di Virgilio S Hellmann KP Robberecht P Multiple differences between wild-type B16 melanoma cells and a wheat germ agglutinin resistant clone Anticancer Res 1991 11 5 1815 1821 1662926
   PubMed Web of Science ®Google Scholar
• Girotti MR Pedersen M Sanchez-Laorden B Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Discov 2013 3 2 158 167 23242808
   PubMed Web of Science ®Google Scholar
• Wroblewski D Mijatov B Mohana-Kumaran N The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance Carcinogenesis 2013 34 2 237 247 23087082
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Carter C Tang L BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004 64 19 7099 7109 15466206
   PubMed Web of Science ®Google Scholar
• Chen J Shao R Zhang XD Chen C Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics Int J Nanomedicine 2013 8 2677 2688 23926430
   PubMed Web of Science ®Google Scholar
• Satyamoorthy K Li G Vaidya B Patel D Herlyn M Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and β-catenin pathways Cancer Res 2001 61 19 7318 7324 11585772
   PubMed Web of Science ®Google Scholar
• Serra V Markman B Scaltriti M NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 2008 68 19 8022 8030 18829560
   PubMed Web of Science ®Google Scholar